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Abstract 
Purpose: To explore the effects of Salvia miltiorrhiza Bge.extract(SMBE) on diethylnitrosamine(DEN)-
induced liver cirrhosis in rats. 
Methods: SMBE was obtained by extracting dried Salvia miltiorrhiza Bge. in water. Liver cirrhosis was 
induced in Wistar rats by injecting diethylnitrosamine in abdominal cavity once a week for 8 weeks. 
Concurrently, rats received either daily oral SMBE (SMBE group) or saline (control group). Clinical 
biochemical assessments, oxidative stress tests (malondialdehyde [MDA], superoxide dismutase 
[SOD]) were performed at 4 and 8 weeks after beginning DEN. 
Results: Compared to the control group, both plasma alanine transaminase (ALT, 245.6 ± 8.5 U/L) and 
aspartate aminotransferase (AST, 205.7 ± 5.1 U/L) were significantly lower in SMBE group after 8 
weeks (p < 0.01 for both ALT and AST). SMBE group exhibited significantly lower MDA (0.41 ± 0.04 
µmol/L) levels and higher SOD(0.53 ± 0.05 U/mg protein) activity than control at 8 weeks after 
commencing DEN (p < 0.01 for both MDA and SOD). 
Conclusion: SMBE has significant ameliorative effect on DEN-induced liver cirrhosis in rats. Anti-
oxidant and anti-apoptotic effects of SMBE appear to be involved in these beneficial effects. 
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Liver cirrhosis is a common pathological 
consequence of chronic liver disease, which is 
characterized by liver fibrosis, scar tissue and 
regenerative nodules, as well as leading to the 
destruction of the hepatic microstructure and liver 
dysfunction [1]. 
 
The structural changes include hepatic sinusoid 
capillarization, portal area and liver lobule fibrosis 
and alterations in microvascular structure. The 
dysfunction is manifested by the deficiency of 
liver function and portal hypertension. The main 
causes of liver fibrosis include hepatitis viruses, 
alcohol, drugs, toxins, schistosome, nonalcoholic 
steatohepatitis (NASH), cholestasis and 
autoimmune liver disease [2,3]. Their persistent 
insults on the liver activate hepatic stellate cells 
(HSCs) in the sinusoid, resulting in the imbalance 
of ECM metabolism. For example, ECM 
overproduction may cause over deposition in 
liver and hepatic structure remodeling. Liver 
fibrosis can progress into liver cirrhosis which 
causes further hepatocellular dysfunction and 
increases intrahepatic resistance to blood flow, 
leading to hepatic insufficiency and portal 
hypertension. Liver cirrhosis is the seventh 
leading cause of disease-related death in the 
United States [4]. Liver fibrosis was considered 
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to be a passive and irreversible process due to 
the collapse of the hepatic parenchyma and its 
substitution with ECM components [5]. However, 
the reversibility of liver fibrosis has now been 
demonstrated both in patients and animal models 
[6]. 
 
Salvia miltiorrhiza Bge is a herb that possesses 
wide-reaching biological activities, including 
coronary artery dilation, improvement of 
myocardial ischemia, and modulation of the 
immune system, as well as antithrombotic, 
antioxidation, anti-aging, antihypoxic, antifatigue, 
anti-inflammatory, anti-hepatic fibrosis, antitumor, 
and analgesia effects[7-12]. As S. miltiorrhiza is 
used in traditional Chinese medicine to prevent 
liver cirrhosis[13], the current study was 
conducted to evaluate the anti-cirrhosis effects of 
the herb in rats. A diethylnitrosamine (DEN)-
induced liver cirrhosis rat model was used, as 
this model closely resembles the cirrhosis 






Herbal samples of S. miltiorrhiza were collected 
from Bozhou City, Anhui Province, China, in May 
2015. Taxonomic identification of the plant was 
performed by Professor HuChe of Zhejiang 
University, China. A voucher specimen of the 
herbarium (no. SMB 201505016) was deposited 
in the College of Pharmacy, Zhejiang University, 
China, for future reference. Aqueous S. 
miltiorrhiza extract (SMBE) was obtained by 
steeping dried S. miltiorrhiza in water at 60 °C for 
1 h. The steeping process was performed three 
times. The sample was then dried in an oven, 
followed by freeze-drying to generate SMBE 
powder. One gram powder was obtained from 
approximately 2.2 g of crude Salvia miltiorrhiza 




Male Wistar rats weighing 180 – 220 gwere 
provided by the Experimental Animal Center of 
Zhejiang Province (Certificate no. SYXK 2006 - 
0008). The animals had free access to food and 
water and were permitted to acclimatize to their 
surroundings for at least 1 week before use. All 
experimental procedures involving the rats were 
approved by the Animal Care and Use 
Committee of Zhejiang University (approval ref 
no. 20100806) and conducted in compliance with 
the Directive 2010/63/EU on the handling of 




The rats were randomly divided into 3 groups of 
10 rats each: 1) normal group: negative controls, 
which were treated with neither DEN nor SMBE; 
2) control group: control rats, which were injected 
with 60 mg DEN once per week for 8 weeks and 
administered oral saline solution once daily for 8 
weeks, beginning just after DEN was started; and 
3) SMBE group: experimental rats, which were 
injected with 60 mg DEN once per week for 8 
weeks and administered 50 mg/kg oral SMBE 





In the 4th and 8th week after beginning DEN 
injections, blood samples (0.5 mL) were obtained 
from each rat by retroorbital sinus puncture and 
collected in heparinized tubes. The blood was 
immediately processed for plasma extraction by 
centrifugation at 3500 g for 15 min. Plasma 
levels of alanine transaminase (ALT) and 
aspartate aminotransferase (AST) were 
measured by spectrophotometry, using 
commercially available kits (Nanjing Jiancheng 
Bioengineering Institute). 
 
Determination of oxidative stress parameters  
 
The rats were sacrificed by cervical dislocation, 
and their livers were excised, rapidly washed, 
and then homogenized in 10 volumes (v/w) of 
ice-cold saline solution. The homogenate was 
centrifuged at 3000 rpm for 10 min, and the 
supernatant was collected for subsequent use 
(as 10 % liver homogenate sample). 
 
The level of malondialdehyde (MDA), a 
biomarker of lipid peroxidation, was determined 
spectrophotometrically by measuring thiobar-
bituric acid reactive substances. One mL of 10 % 
trichloroacetic acid and 1 mL of 0.67 % 
thiobarbituric acid were added to 0.2 mL of the 
10 % liver homogenate. The mixtures were 
incubated at 100 oC for 15 min. After cooling and 
centrifugation, the supernatant was aspirated 
and its absorbance (A) values at 532 nm and 600 
nm were determined using water as blank. MDA 
concentration was calculated as in Eq 1. 
 
MDA (μmol/L) = 6.45 (A532 – A600) ………. (1) 
 
The superoxide dismutase (SOD) activity was 
measured spectrophotometrically, using 
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commercially available SOD kit, A001-1 (Nanjing 




Data are presented as mean ± standard 
deviation (SD). The results were analyzed using 
one-way analysis of variance followed by Tukey’s 
multiple comparison tests. SPSS 16.0 software 
for Windows was used for the statistical 
analyses. Differences with p < 0.05 were 




Effect of SMBE on ALT and AST levels in liver 
cirrhosis  
 
During the weekly DEN injections, the body 
weight of the rats gradually decreased. After 4 
weeks of DEN injections, the rats entered the 
hepatitis stage. DEN administration alone 
induced marked increases in plasma ALT and 
AST activity, whereas no increase in either 
enzyme was observed in the normal group (p < 
0.01 for control vs. normal group at 4 weeks) 
(Tables 1 and 2). SMBE ameliorated this 
increase in ALT and AST: at 4 weeks both the 
ALT and AST were significantly lower in the 
control group than in the normal group (p < 0.01). 
After the 8th week of DEN injections, liver 
cirrhosis was present in both the model and 
SMBE groups. Plasma concentrations of ALT 
and AST in the control group at 8 weeks were 
significantly lower than in the control group at 4 
weeks (p < 0.05), but they remained higher than 
in the normal group (p < 0.05 for model vs. 
normal group at 8 weeks) (Tables 1 and 2). 
Plasma concentrations of ALT and AST were 
significantly lower in the SMBE group than in the 
control group at 8 weeks (p < 0.01). 
 
Table 1: Effect of SMBE on plasma ALT (U/L) 
 
Group 0 week 4 weeks 8 weeks 
Normal 112.5±3.6 87.5±4.9 112.5±4.1 
Control 110.8±3.2 497.3±10.8** 245.6±8.5* 
SMBE 108.2±3.7 161.4±6.3△△ 128.7±5.7△△ 
*P < 0.05，**p < 0.01 vs. normal group; △p < 0.05，
△△p < 0.01 vs. control group 
 
Table 2: Effect of SMBE on plasma AST (U/L) 
 
Group 0 week 4 weeks 8 weeks 
Normal 112.5±4.4 112.8±4.6 121.4±4.8 
Control 108.7±3.9  358.2±9.5** 205.7±5.1* 
SMBE 105.3±4.2  128.4±5.9△△ 138.6±4.2△△ 
*p < 0.05，** p < 0.01 vs. normal group; △p < 0.05，△△p 
< 0.01 vs. control group 
 
Table 3: Effect of SMBE on MDA levels and SOD 
activity in rat livers 
 
Group  MDA(µmol/L) SOD(U/mg protein) 
Normal 0.07±0.02** 0.93±0.14** 
Control 0.41±0.04 0.53±0.05 
SMBE 0.12±0.03** 0.71±0.03** 
*P < 0.05，**p < 0.01 vs. control group; MDA = 
malondialdehyde; SOD = superoxide dismutase 
 
Effect of SMBE on hepatic MDA and SOD in 
liver cirrhosis  
 
Levels of MDA, a marker of oxidative stress, 
were significantly increased in DEN-treated 
control group rats (p < 0.01 for control vs. normal 
group) (Table 3). SMBE significantly reduced 
MDA formation in DEN-treated rat livers (p < 
0.01 for SMBE vs. control group). Furthermore, 
SOD activity was significantly higher in the livers 
of rats treated with SMBE than in the livers of 
cirrhotic rats that did not receive SMBE (p < 0.01 




Liver fibrosis is characterized by overproduction 
and irregular deposition of extracellular matrix 
(ECM) in liver tissues, leading to the distortion of 
hepatic microstructure and liver dysfunction. 
Antifibrotic strategies against liver fibrosis include 
early intervention or control of etiologies, hepatic 
inflammation prevention and regulation of hepatic 
ECM metabolism and stellate cell activation. Viral 
hepatitis is the most important antecedent factor 
for liver fibrosis. Tremendous progress has been 
made in targeted antiviral treatment in recent 
years. Recent evidence showed that liver fibrosis 
could regress with effective antiviral treatment 
[15]. 
 
In recent years, many researchers have studied 
the anti-fibrosis properties of traditional Chinese 
medicine. The current study demonstrates that 
oral administration of SMBE exhibits the 
ameliorative effects on liver fibrosis and cirrhosis 
induced by DEN in rats. Potential mechanisms 
for these beneficial effects include the anti-
necrosis, anti-apoptotic, and anti-inflammatory 
actions of SMBE, and/or SMBE-mediated 
reduction of activated hepatic stellate cells [16]. 
 
MDA, an end-product of lipid peroxidation, was 
significantly increased in our rat model of liver 
cirrhosis [17]. SMBE reduced MDA formation and 
also increased SOD activity in DEN-treated rats. 
SMBE likewise inhibited DEN-induced fibrosis, 
which appears to have been mediated by 
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SMBE’s anti-oxidant activity. Furthermore, SMBE 
reduced plasma ALT and AST levels at both 4 
and 8 weeks after beginning DEN injections, 
compared to DEN-treated rats that did not 
receive SMBE. All of these results suggest that 
SMBE attenuated apoptosis and oxidative stress 
in the fibrotic liver. Therefore, SMBE may be a 





SMBE has significant ameliorative effects on 
DEN-induced liver cirrhosis in rats. The 
mechanism for inhibition of the fibrotic process 
appears to involve the anti-oxidant and anti-
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